MTVA: 8-Week Data for 48 mg Cohort in Phase 1 Obesity Study Expected Before End of 2025
On November 6, 2025, MetaVia Inc. (MTVA) announced financial results for the third quarter of 2025 and provided a business update. We anticipate...
134 Views
MTVA: Results from 8-week Study of 48 mg DA-1726 Expected Before End of 2025
On August 7, 2025, MetaVia Inc. (MTVA) announced financial results for the second quarter of 2025 and provided a business update. The company...
128 Views
MTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model
On June 21, 2025, MetaVia Inc. (MTVA) announced the presentation of preclinical data for DA-1241, the company's novel GPR119 agonist, that showed...
276 Views
MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study
On May 14, 2025, MetaVia Inc. (MTVA) announced financial results for the first quarter and provided a business update. The company recently...
212 Views
MTVA: Positive Phase 1 MAD Data for DA-1726 Excellent Tolerability Profile and Mean Day 26 Weight Loss of 4.3%
On April 15, 2025, MetaVia Inc. (MTVA) announced positive results from the 4-week Phase 1 multiple ascending dose (MAD) trial of DA-1726 for the...
577 Views